Trials / Not Yet Recruiting
Not Yet RecruitingNCT06131216
Phase I Study of SHR-2022 Injection in the Treatment of Patients With Advanced Malignant Tumors
Phase I Clinical Study on the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-2022 Injection Alone or in Combination With Other Anti-tumor Treatments in Patients With Advanced Malignant Tumors
- Status
- Not Yet Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 116 (estimated)
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the safety and tolerability of SHR-2022 in patients with advanced malignancies and to determine MTD or MAD versus RP2D
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR-2022 Injection | SHR-2022 Injection is administered by intravenous (IV) infusion |
Timeline
- Start date
- 2023-12-01
- Primary completion
- 2026-12-01
- Completion
- 2026-12-01
- First posted
- 2023-11-14
- Last updated
- 2023-11-14
Source: ClinicalTrials.gov record NCT06131216. Inclusion in this directory is not an endorsement.